Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).

Autor: Kharitonova T; Department of Acute Cerebrovascular Pathology and Emergency Neurology, Sankt-Peterburgskij naucno-issledovatel'skij institut skoroj pomosi imeni I I Dzanelidze, Sankt Peterburg, Russian Federation tvh2001@mail.ru., Shvarts YG; Department of Faculty Therapy, City Clinical Hospital, Saratov, Russian Federation., Verbovoy AF; Department of Endocrinilogy, Limited Liability Company 'Center Diabetes', Samara, Russian Federation., Orlova NS; Endocrinologist, 'Eco-Safety' Medical Center, St Petersburg, Russian Federation., Puzyreva VP; City Endocrinology Center, City Hospital No 4, Rostov-on-Don, Russian Federation., Strokov IA; Department of Nervous Diseases and Neurosurgery, Sechenov University, Moskva, Russian Federation.

Publikováno v: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2022 Jun; Vol. 10 (3).

A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.

Autor: Shestakova MV; Endocrinology Research Centre, Diabetes Institute, Moscow, Russia. Electronic address: shestakova.mv@gmail.com., Wilding JPH; Obesity and Endocrinology Research, Institute of Ageing and Chronic Disease, Clinical Sciences Centre, University of Liverpool, Liverpool, United Kingdom., Wilpshaar W; Astellas Pharma Europe B.V., Leiden, Netherlands., Tretter R; Astellas Pharma Europe B.V., Leiden, Netherlands., Orlova VL; Autonomous Noncommercial Organization 'Medical Centre 'XXI century', St. Petersburg, Russia., Verbovoy AF; Diabetes Center, Samara, Russia.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2018 Dec; Vol. 146, pp. 240-250. Date of Electronic Publication: 2018 Nov 01.

[Obesity and cardiovascular system].

Autor: Verbovoy AF, Pashentseva AV, Sharonova LA

Publikováno v: Klinicheskaia meditsina [Klin Med (Mosk)] 2017; Vol. 95 (1), pp. 31-5.

[Osteoprotegerin is a new marker of cardiovascular diseases].

Autor: Verbovoy AF; Samara State Medical University, Health Ministry of Russia, Samara, Russia., Tsanava IA; Samara State Medical University, Health Ministry of Russia, Samara, Russia., Mitroshina EV; Samara State Medical University, Health Ministry of Russia, Samara, Russia., Sharonova LA; Samara State Medical University, Health Ministry of Russia, Samara, Russia.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2017; Vol. 89 (4), pp. 91-94.

Hypothyroidism and cardiovascular system.

Autor: Verbovoy AF, Sharonova Lyudmila A, Kosareva OV, Verbovaya NI, Dolgikh YA

Publikováno v: Klinicheskaia meditsina [Klin Med (Mosk)] 2016; Vol. 94 (7), pp. 497-503.